Top
Main

All outcomes

Feedback
Home
Top   Main   All Outcomes
Loading...
Home   COVID-19 treatment studies for Bromhexine  COVID-19 treatment studies for Bromhexine  C19 studies: Bromhexine  Bromhexine   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Cannabidiol (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Favipiravir (meta) Sotrovimab (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Melatonin (meta)

Other Treatments Global Adoption
Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Bromhexine for COVID-19: real-time meta analysis of 6 studies
Covid Analysis, January 22, 2022, DRAFT
https://c19bromhexine.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ansarin (RCT) 91% 0.09 [0.01-1.59] death 0/39 5/39 Improvement, RR [CI] Treatment Control Ansarin (RCT) 89% 0.11 [0.01-0.84] ventilation 1/39 9/39 Ansarin (RCT) 82% 0.18 [0.04-0.77] ICU 2/39 11/39 Li (RCT) 75% 0.25 [0.06-1.00] no disch. 2/12 4/6 Li (RCT) 50% 0.50 [0.09-2.73] oxygen 2/12 2/6 Mareev (RCT) 39% 0.61 [0.14-0.97] no disch. 14/24 20/21 Mareev (RCT) 87% 0.13 [0.01-2.25] viral+ 0/17 3/13 Tolouian (RCT) 76% 0.24 [0.01-8.03] death 48 (n) 52 (n) Tolouian (RCT) 76% 0.24 [0.01-7.69] no improv. 48 (n) 52 (n) Tolouian (RCT) -75% 1.75 [1.13-2.71] cases 29/48 18/52 Mikhaylov (RCT) 80% 0.20 [0.01-3.97] hosp. 0/25 2/25 Mikhaylov (RCT) 91% 0.09 [0.01-1.56] symp. case 0/25 5/25 Mikhaylov (RCT) 71% 0.29 [0.07-1.24] viral+ 2/25 7/25 Tolouian (DB RCT) 33% 0.67 [0.04-10.5] death 0/187 1/185 Tolouian (DB RCT) 70% 0.30 [0.05-1.78] hosp. 1/187 6/185 Tolouian (DB RCT) 53% 0.47 [0.25-0.87] symp. case 16/187 34/185 Tolouian (DB RCT) 50% 0.50 [0.24-0.99] cases 13/187 26/185 bromhexine COVID-19 outcomes c19bromhexine.com Jan 22, 2022 Favors bromhexine Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Submit